Annual EBITDA:
-$2.88M+$64.57M(+95.74%)Summary
- As of today, SPRY annual EBITDA is -$2.88 million, with the most recent change of +$64.57 million (+95.74%) on December 31, 2024.
- During the last 3 years, SPRY annual EBITDA has risen by +$16.37 million (+85.06%).
- SPRY annual EBITDA is now at all-time high.
Performance
SPRY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$52.80M-$5.47M(-11.55%)Summary
- As of today, SPRY quarterly EBITDA is -$52.80 million, with the most recent change of -$5.47 million (-11.55%) on September 30, 2025.
- Over the past year, SPRY quarterly EBITDA has dropped by -$31.07 million (-143.02%).
- SPRY quarterly EBITDA is now -211.50% below its all-time high of $47.35 million, reached on December 31, 2024.
Performance
SPRY Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$89.68M-$31.07M(-53.02%)Summary
- As of today, SPRY TTM EBITDA is -$89.68 million, with the most recent change of -$31.07 million (-53.02%) on September 30, 2025.
- Over the past year, SPRY TTM EBITDA has dropped by -$29.23 million (-48.37%).
- SPRY TTM EBITDA is now -3019.23% below its all-time high of -$2.88 million, reached on December 31, 2024.
Performance
SPRY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SPRY EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +95.7% | -143.0% | -48.4% |
| 3Y3 Years | +85.1% | -697.2% | -107.9% |
| 5Y5 Years | +87.2% | -317.9% | -281.0% |
SPRY EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +95.7% | -211.5% | at low | -3019.2% | at low |
| 5Y | 5-Year | at high | +95.7% | -211.5% | at low | -3019.2% | at low |
| All-Time | All-Time | at high | +95.7% | -211.5% | at low | -3019.2% | at low |
SPRY EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$52.80M(-11.5%) | -$89.68M(-53.0%) |
| Jun 2025 | - | -$47.34M(-28.3%) | -$58.60M(-120.4%) |
| Mar 2025 | - | -$36.90M(-177.9%) | -$26.59M(-824.9%) |
| Dec 2024 | -$2.88M(+95.7%) | $47.35M(+318.0%) | -$2.88M(+95.2%) |
| Sep 2024 | - | -$21.73M(-41.8%) | -$60.44M(-6.7%) |
| Jun 2024 | - | -$15.32M(-16.2%) | -$56.67M(+8.5%) |
| Mar 2024 | - | -$13.18M(-29.0%) | -$61.94M(+8.2%) |
| Dec 2023 | -$67.45M(-91.6%) | -$10.21M(+43.1%) | -$67.45M(-17.8%) |
| Sep 2023 | - | -$17.96M(+12.8%) | -$57.23M(-24.7%) |
| Jun 2023 | - | -$20.58M(-10.1%) | -$45.90M(-44.8%) |
| Mar 2023 | - | -$18.69M(-182.2%) | -$31.70M(+26.5%) |
| Dec 2022 | -$35.20M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$6.62M(-3.8%) | -$43.13M(+26.5%) |
| Jun 2022 | - | -$6.38M(+9.5%) | -$58.65M(+23.1%) |
| Mar 2022 | - | -$7.05M(+69.5%) | -$76.28M(+13.0%) |
| Dec 2021 | -$19.24M(+38.3%) | - | - |
| Dec 2021 | - | -$23.08M(-4.2%) | -$87.66M(-13.5%) |
| Sep 2021 | - | -$22.14M(+7.8%) | -$77.21M(-40.2%) |
| Jun 2021 | - | -$24.02M(-30.4%) | -$55.07M(-48.4%) |
| Mar 2021 | - | -$18.42M(-45.8%) | -$37.12M(-57.7%) |
| Dec 2020 | -$31.21M(-38.6%) | -$12.64M(-108.5%) | -$23.54M(-35.0%) |
| Jun 2020 | - | -$6.06M(-25.2%) | -$17.44M(-53.3%) |
| Mar 2020 | - | -$4.84M(+25.9%) | -$11.38M(-74.1%) |
| Dec 2019 | -$22.52M(-33.3%) | -$6.54M | -$6.54M |
| Dec 2018 | -$16.90M | - | - |
FAQ
- What is ARS Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for ARS Pharmaceuticals, Inc.?
- What is ARS Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is ARS Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for ARS Pharmaceuticals, Inc.?
- What is ARS Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is ARS Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for ARS Pharmaceuticals, Inc.?
- What is ARS Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is ARS Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of SPRY is -$2.88M
What is the all-time high annual EBITDA for ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals, Inc. all-time high annual EBITDA is -$2.88M
What is ARS Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, SPRY annual EBITDA has changed by +$64.57M (+95.74%)
What is ARS Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of SPRY is -$52.80M
What is the all-time high quarterly EBITDA for ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals, Inc. all-time high quarterly EBITDA is $47.35M
What is ARS Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, SPRY quarterly EBITDA has changed by -$31.07M (-143.02%)
What is ARS Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of SPRY is -$89.68M
What is the all-time high TTM EBITDA for ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals, Inc. all-time high TTM EBITDA is -$2.88M
What is ARS Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, SPRY TTM EBITDA has changed by -$29.23M (-48.37%)